HC Wainwright & Co. Reiterates Buy on Mural Oncology, Maintains $18 Price Target

Benzinga · 03/12 11:29
HC Wainwright & Co. analyst Andres Maldonado reiterates Mural Oncology (NASDAQ:MURA) with a Buy and maintains $18 price target.